Avant Diagnostics, Inc. (AVDX) Ovarian Cancer Early

New Post Public Reply Private Reply Replies (0) Message Board
QualityStocks
Avant Diagnostics, Inc. (AVDX) Ovarian Cancer Early Detection Diagnostic Tech Bolstered Mightily By Amarantus Bioscience Merger

According to recent analysis out late last year from the world’s second largest publisher of premium market reports, MarketsandMarkets, the global market for biomarkers is on-track to grow at a CAGR of 13.58 percent through 2020, reaching upwards of $45.55 billion on the strength of increasing healthcare, as well as R&D spending. A key driver of this growth is the massive importance of biomarkers as an objective means for calculating a pathogenic or pharmacological response to therapeutics, or to gauge the behavior of a normal biological process. Biomarker technology continues to play a pivotal role when it comes to developing cutting-edge diagnostics for ailments such as cancer.

Indeed, the global cancer biomarkers market will continue to be one of the most active segments moving forward according to M&M, and this segment is slated to run at an 11.6 percent CAGR over the same interval. Driven by major players engaged in personalized medicine and molecular diagnostics involving biomarkers, such as global microarray market leader Affymetrix (NASDAQ: AFFX), which was recently reported as having been acquired by competitor Thermo Fisher Scientific (NYSE: TMO) for approximately $1.3 billion, as well as more investor-accessible players, some of whom may have at their disposal technologies that hold the potential to reshape the industry itself.

Such high-profile M&A activity at the heart of the translational research/microarray sector speaks volumes for how hot the space has become, and how much promise it holds for the future of medicine. One of the areas in oncology diagnostics that bears consideration is ovarian cancer, due to the specific challenges and concerns associated with the space. American Cancer Society data indicates that roughly 21,300 women in the U.S. alone were diagnosed with ovarian cancer last year, leading to approximately 14,200 tragic deaths. With an overall five-year survival rate of only 45 percent, ovarian cancer is the fifth most common cause of cancer-related death among women, and the risk is highest in women over the age of 55.

Given the high five-year survivability rate of around 93 percent for ovarian cancer, if it is detected in the early stage in which the symptoms are often ignored – compared to an only 18 percent five-year survivability rate if it is detected in later stages – the benefits of advanced warning and pre-symptomatic screening using a definitive, cost-effective diagnostic test cannot be overstated. This is especially true for patients who are found to have platinum-resistant/refractory ovarian cancer, as such patients have an extremely poor prognosis and may also be classed as having chemotherapy-resistant/refractory ovarian cancer.

The standard approach to ovarian cancer utilizes the combination of a platinum compound such as Bristol-Myers Squibb’s (NYSE: BMY) (OTC: BMYMP) Platinol® (cisplatin) or Paraplatin® (carboplatin), and a Taxane, such as Sanofi’s (NYSE: SNY) Taxotere® (docetaxel), or Phyton Biotech’s Taxol® (paclitaxel). But for patients with platinum-resistant/refractory ovarian cancer, early detection is really the brass ring, even with such good news out recently as Merck (NYSE: MRK) and Pfizer (NYSE: PFE) receiving FDA approval for the first Phase III study of avelumab, an investigational, fully human PD-L1 (programmed death-ligand 1) inhibitor that could emerge as a treatment for platinum-resistant/refractory ovarian cancer.

Suffice it to say, this is a market ripe for a simplified microarray-based blood test for early detection of ovarian cancer, including tests like Avant Diagnostics’ (OTCQB: AVDX) OvaDx®, which possesses numerous advantages over the standard CA 125 protein biomarker test for ovarian cancer. Advantages include a sample size of only a few drops and the elimination of needle blood draws, factors which allow for high-volume screening throughput at even smaller facilities. A simplified test like OvaDx, which uses sample shipping and storage on room temperature blood cards and nevertheless yields definitive diagnostic results that allow for detection of early stage ovarian tumor cell development, is a real triumph for women’s health. OvaDx could be a game changer for the $2 billion plus ovarian cancer diagnostic market and might just put AVDX in the immuno-oncology pole position.

The recent announcement that AVDX has entered into an LOI with regenerative medicine, neurology and orphan disease-focused Amarantus Bioscience Holdings (OTCQX: AMBS) to merge the wholly-owned diagnostics subsidiary of Amarantus into AVDX is further proof of how hot the sector is overall. Amarantus Diagnostics’ MSPrecise®, a neuroimmunology-based sequencing assay for multiple sclerosis, also adds mightily to AVDX’s already promising diagnostics footprint. The $1 billion market potential possible in addressing the woefully inaccurate diagnostics market for multiple sclerosis stands to make the combined company a force to be reckoned with. Adding to this emerging diagnostic juggernaut’s appeal is the $3 billion potential of Amarantus Diagnostics’ LymPro Test® for Alzheimer’s disease, another early detection-focused marvel that could revolutionize treatment options for Alzheimer’s patients.

For more information, visit www.avantdiagnostics.com

Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com

Avant Diagnostics, Inc. (AVDX) Stock Research Links

AVDX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sports Leagues Confront Youth Gambling's Hard Truth

Updated Category News Views 70

A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 36

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
COFE+ Barista Test Puts Robotic Coffee on the Clock

Updated Category News Views 84

A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 118

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 45

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 125

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 77

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading

Top 5 Most Recently Viewed Articles

Freddie Mac's 30-Year Mortgage Rate Decreases Slightly

Updated Category News Views 219

Freddie Mac Reports on Mortgage Rates In recent reports from Freddie Mac, there's good news for potential homebuyers. The 30-year fixed-rate mortgage (FRM) has seen a slight decline, which is a welcome change in a fluctuating market. This current value sits at an average of 6.64%, reflecting a small drop from the previous week's average of 6.65%. Understanding the Current...

Continue Reading
Sports.com Partners with SEGG Media for Soccerex Event

Updated Category News Views 251

Sports.com Joins SEGG Media as Title Sponsor at Soccerex Miami 2025 MIAMI BEACH, Fla. — SEGG Media Corporation (NASDAQ: SEGG, LTRYW) has officially announced that Sports.com will take on the role of Title Sponsor for the engaging Soccerex Miami event happening at the Miami Beach Convention Center. This sponsorship reflects a significant commitment to promoting...

Continue Reading
Gastech 2025: A Global Convergence for Energy Innovations

Updated Category News Views 249

Gastech 2025 Unites the World of Energy Innovation Gastech 2025 welcomes more than 50,000 attendees from over 150 countries, establishing Milan as the global center for critical dialogues on energy supply, transformation, and innovation. This event has become a vital platform for high-level conversations that shape the future of energy. Leadership at Gastech 2025...

Continue Reading
Baird Confirms Outperform Rating for Costco Amidst Strong Growth

Updated Category News Views 68

Strong Sales Performance Driving Costco's Success Baird has reaffirmed its Outperform rating for Costco Wholesale (NASDAQ: COST), while upholding a price target of $975. The firm's latest insights indicate that Costco's global core comparable sales, excluding gas and foreign exchange influences, have surged by 8.9%. Such a rise is significant and demonstrates the...

Continue Reading
Celebrating a Decade of DNBSEQ™: Innovations and Impact

Updated Category News Views 290

Celebrating a Decade of DNBSEQ™ Technology MGI Tech Co., Ltd. (NASDAQ: MGI) is thrilled to celebrate ten years of its revolutionary DNBSEQ™ sequencing technology. This milestone marks a significant journey in transforming the landscape of genomics, offering solutions that not only enhance scientific research but also make genomic information more accessible to a...

Continue Reading